AMARIN CORP PLC -ADR (AMRN)       1.1  +0.01 (+0.92%)

1.1  +0.01 (+0.92%)

US0231112063 - ADR - After market: 1.06 -0.04 (-3.64%)


Fundamental Rating

2

Taking everything into account, AMRN scores 2 out of 10 in our fundamental rating. AMRN was compared to 638 industry peers in the Biotechnology industry. AMRN has a medium profitability rating, but doesn't score so well on its financial health evaluation. AMRN has a expensive valuation and it also scores bad on growth




Profitability

Profitability Rating

4

AMRN's Return On Assets of -10.27% is amongst the best returns of the industry. AMRN outperforms 88% of its industry peers. The industry average Return On Assets is -41.19%.
AMRN's Profit Margin of -21.02% is amongst the best returns of the industry. AMRN outperforms 83% of its industry peers. The industry average Profit Margin is -408.39%.

The profitability ratios for AMRN are negative, so there is not much use analyzing them.
The Piotroski-F score of AMRN is 1.00. This is a very weak score and indicates problems in health and profitability for AMRN.
VS Industry

ROA (-10.27%) VS Industry: 88% outperformed.

-1,441.42
115.38

Profit Margin (-21.02%) VS Industry: 83% outperformed.

-1,173,705.71
8,610.80

Valuation

Valuation Rating

2

With a price book ratio of 0.76, AMRN is valued rather cheaply.
Compared to an average industry price book ratio of 1.59, AMRN is valued rather cheaply

The Price/Earnings Ratio is negative for AMRN. In the last year negative earnings were reported.
Also next year AMRN is expected to report negative earnings again, which makes the also the Forward Price/Earnings Ratio negative.
VS Industry

Price/Book (0.76) VS Industry: 72% outperformed.

162.47
0.08

Growth

Growth Rating

2

AMRN shows a strong growth in Revenue. Measured over the last 5 years, the Revenue has been growing by 34.99% yearly.
Based on estimates for the next 5 years, AMRN will show a decrease in Revenue. The Revenue will decrease by -8.02% on average per year.
AMRN shows a strong negative growth in Earnings Per Share. In the last year the EPS decreased by -1900.00%.

The Earnings Per Share is expected to decrease by -55.26% on average over the next 5 years. This is quite bad
AMRN shows a very negative growth in Revenue. In the last year, the Revenue has decreased by -23.34%.
When comparing the Revenue growth rate of the last years to the growth rate of the upcoming 5 years, we see that the growth is decreasing.

PastFuture
5Y3Y1Y1Y2Y3Y5Y
EPSN/A N/A -1900% -1181.2% -195.21% -76.66% -55.26%
Revenue34.99% 36.52% -23.34% -38.24% -24.47% -13.78% -8.02%

Health

Health Rating

2

A Current Ratio of 1.99 indicates that AMRN should not have too much problems paying its short term obligations.
AMRN has a Quick Ratio of 1.36. This is a normal value and indicates that AMRN is financially healthy and should not expect problems in meeting its short term obligations.
The Debt to Equity ratio of AMRN is in line with the industry averages.
AMRN has a Altman-Z score comparable to the industry average, which is at -0.10.

Compared to an average industry Current Ratio of 6.52, AMRN is worse placed to pay its short term obligations than its industry peers. 87% of its industry peers have a better Current Ratio.
When comparing the Quick Ratio of AMRN to the average industry Current Ratio of 6.48, AMRN is less able to pay its short term obligations than its industry peers. 91% of its industry peers have a better Quick Ratio.
Based on the Altman-Z score of -0.90, we must say that AMRN is in the distress zone and has some risk of bankruptcy.
The Piotroski-F score of AMRN is 1.00. This is a very weak score and indicates problems in health and profitability for AMRN.
VS Industry

Debt/Equity (0) VS Industry: 43% outperformed.

18.24
0.00

Quick Ratio (1.36) VS Industry: 9% outperformed.

0.03
399.16

Current Ratio (1.99) VS Industry: 13% outperformed.

0.08
401.12

Altman-Z (-0.9) VS Industry: 45% outperformed.

-1,821.48
293.92

Dividend

Dividend Rating

0

No dividends for AMRN!.

AMRN Daily chart

AMARIN CORP PLC -ADR1.1

NASDAQ:AMRN (9/26/2022, 7:00:00 PM)+0.01 (+0.92%)

After market: 1.06 -0.04 (-3.64%)

Chartmill FA Rating
GICS Sector Health Care
GICS IndustryGroup Pharmaceuticals, Biotechnology & Life Sciences
GICS Industry Biotechnology
Earnings (Last) 08-03 2022-08-03/bmo Earnings (Next) N/A N/A
Ins Owners 0.43% Inst Owners 33.83%
Market Cap 443.53M Analysts 52.31
Valuation
PE N/A Fwd PE N/A
PEG (NY) N/A PEG (5Y) N/A
P/S 0.93 P/B 0.76
EV/EBITDA -2.74
Dividend
Dividend Yield N/A Dividend Growth N/A
DP N/A Ex-Date N/A
Growth
EPS 1Y -1900% EPS 3Y N/A
EPS 5Y N/A EPS growth Q2Q -650%
EPS Next Y -1181.2% EPS Next 2Y -195.21%
EPS Next 3Y -76.66% EPS Next 5Y -55.26%
Revenue growth 1Y -23.34% Revenue growth 3Y 36.52%
Revenue growth 5Y 34.99% Revenue growth Q2Q -38.87%
Revenue Next Year -38.24% Revenue Next 2Y -24.47%
Revenue Next 3Y -13.78% Revenue Next 5Y -8.02%
Health
Current Ratio 1.99 Quick Ratio 1.36
Altman-Z -0.9 F-Score 1
Debt/Equity 0
Profitability
ROA -10.27% ROE N/A
ROIC N/A ROICg N/A
PM -21.02 OM -10.33
Asset Turnover 0.49

Fundamental Stock Screener Links

Screen Image

Fundamental Stock Screener

Find stocks with similar Fundamental rating on the USA

Screen Image

Best Fundamental Competitors Stock Screener

Find the competitors with the best fundamentals on the USA

Screen Image

Best Valuation Competitors Stock Screener

Find the competitors with the best valuation on the USA

Screen Image

Best Dividend Competitors Stock Screener

Find the competitors with the best dividend on the USA